An interventional study of MyPlan / Movisalud App in Endometriosis, sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. Completed at 1 site in Spain. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Not applicable, Interventional, and Supportive care
The working hypothesis that is intended to be evaluated with this study is that the use of mobile health applications and telemedicine in the follow-up of patients affected by endometriosis offers greater satisfaction and improves the quality of care.
The patients included in the control group will be followed up according to the center's usual care protocol. Those patients included in the intervention group will be monitored through telemedicine tools including mobile health.
To evaluate the satisfaction of the application of a telemedicine program (mobile health and eConsulta) in the follow-up of the patient affected by endometriosis.
Endometriosis is a chronic inflammatory disease that affects women where the endometrial tissue is located outside its normal location, predominantly in the pelvis, including the ovaries, pelvic ligaments and peritoneal surfaces, as well as the bladder or intestine. The presentation of the disease is diverse and ranges from superficial peritoneal lesions, ovarian endometriotic cysts, to nodules that infiltrate the tissues >5mm (deep endometriosis), all accompanied by fibrotic processes and pelvic adhesions.
The clinic of this entity is characterized by cyclical pelvic pain coinciding with menstruation, which can be accompanied by dyspareunia, dyschezia, dysuria, hematuria or rectal bleeding. In addition to the serious impact on their quality of life, these patients have much higher rates of infertility compared to the general population.
The incidence of endometriosis in the general population is difficult to quantify due to the fact that the definitive diagnosis is achieved after the direct visualization of lesions at the time of surgery, and after its anatomo-pathological study. Despite this, it is estimated that this disease affects 10% of the general population, reaching figures of 35% in symptomatic patients.
The non-specificity of the symptoms causes a diagnostic delay of approximately 8 years from the patient's first consultation, causing this disease to be detected in more advanced stages. An early diagnosis, quick access to specialized units and correct follow-up are essential to improve the quality of life of patients affected by endometriosis.
The treatments currently available for endometriosis are divided into analgesic treatments for pain control, hormonal treatments to stop the progression of the disease, and surgical treatments in patients refractory to medical treatments. Due to the fact that it is a chronic disease with the possibility of progression, the patient may require long periods of medical treatment. The side effects associated with these, the variation in response to these and the possibility of needing surgery, require a regular follow-up of these patients in the medical consultation(7,8).
Due to the need to take an anamnesis, complete physical examination and a pelvic ultrasound for the initial evaluation of the patient with suspected endometriosis, the first visit should always be done in person. Once the case has been identified and medical treatment instituted, the second visits are limited to a follow-up to assess symptoms, control adherence to treatment and the need to modify therapeutic guidelines. These follow-up visits do not require a mandatory presence and can be replaced by remote visits through information and communication technologies (ICTs).
The working hypothesis that is intended to be evaluated with this study is that the redefinition of the current care route for the patient affected by endometriosis through the incorporation of new interdisciplinary digital health tools will improve the degree of satisfaction of the users involved (patients and professionals healthcare), reduce the consumption of healthcare resources and improve the clinical management of patients.
Main objective To evaluate the satisfaction of patients affected by endometriosis after the incorporation of a follow-up program based on telemedicine (mobile health and eConsulta) by means of a randomized, longitudinal, prospective experimental, interventional clinical trial.
Secondary objectives
901 studies on the registry are indexed under Endometriosis; 259 are open to participants now.
This study's enrollment of 60 is close to the median of 64 across 525 interventional studies indexed under Endometriosis.
Browse Endometriosis studies →Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau is the lead sponsor of 335 studies on the registry; 64 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Usual care control according to the protocol of the center for follow-up on-site visits of endometriosis affected patients.
Those patients included in the intervention group will be monitored through telemedicine tools including mobile health, in addition to the usual on-site visits
Device: MyPlan / Movisalud App
Those patients in experimental arm will be followed through a mobile app that offers different functionalities designed to improve clinical-patient communication, empower the patient in the management of his disease and treatment, detect symptoms early and individualize the interventions of professionals thanks to the patient records on the platform
Satisfaction with the assistance received assessed through the Client Satisfaction Questionnaire (CSQ-8)
Patient's satisfaction with the follow-up carried out through the study period. It will be measured through the Client Satisfaction Questionnaire (CSQ-8) at the beginning and at 6 months. The Client Satisfaction Questionnaire is an 8 item measure of client satisfaction with services. The items for the CSQ-8 were selected on the basis of ratings by mental health professionals of a number of items that could be related to client satisfaction and by subsequent factor analysis. The CSQ-8 is unidimensional, yielding a homogenous estimate of general satisfaction with services. Total scores range from 8 to 32, with the higher number indicating greater satisfaction.
Time frame: 6 months
Satisfaction with the assistance received through a 5-point Likert-type survey designed for the study
Patient's satisfaction with the follow-up carried out through the study period. It will be measured through a 5-point Likert-type survey designed for the study (Annex 2) at the beginning and at 6 months.
Time frame: 6 months
Therapeutic adherence assessed through Adherence to Refills and Medications Scale (ARMS-e) questionnaire
The Adherence to Refills and Medications Scale (ARMS-e) questionnaire is a validated tool designed to measure patient adherence to medication regimens, particularly focusing on refill behaviors and proper medication intake. It is widely used in clinical and research contexts to assess adherence among patients with chronic conditions or complex medication schedules. The ARMS-e is composed of items addressing difficulties patients face in obtaining and taking their medications as prescribed, including forgetfulness, understanding instructions, or logistical barriers like transportation. Scores for the ARMS-e range from a minimum of 12 (indicating perfect adherence with no issues) to a maximum of 48 (indicating severe non-adherence and significant challenges in following the prescribed regimen). Lower scores reflect better adherence, while higher scores suggest greater non-adherence.
Time frame: At the beginning, at 3 and at 6 months.
Therapeutic adherence using the Haynes-Sackett questionnaire
The Haynes-Sackett Questionnaire is a tool used to evaluate patient adherence to prescribed medical treatments. Commonly applied in clinical and research settings, it identifies whether patients consistently follow therapeutic recommendations. The questionnaire includes questions designed to explore patient behaviors and attitudes toward medication adherence, often addressing reasons for non-adherence and the frequency of missed doses. Scores range from 0 to 100, with 0 indicating no adherence and 100 reflecting full adherence. High scores (80-100) suggest consistent adherence, which is typically associated with better clinical outcomes. Moderate scores (50-79) indicate partial adherence, highlighting areas where improvements may be necessary. Low scores (\<50) reveal significant non-adherence, which can compromise treatment effectiveness. Clinically, the Haynes-Sackett Questionnaire is used to identify barriers to adherence, such as side effects or financial challenges, design interve
Time frame: At the beginning, at 3 and at 6 months.
Changes on quality of life (Endometriosis specific) assessed through theEndometriosis Health Profile-30 (EHP-30)
The Endometriosis Health Profile-30 (EHP-30) questionnaire is a condition-specific tool designed to assess the health-related quality of life (HRQoL) in individuals with endometriosis. It captures the physical, emotional, and social impact of the condition through 30 items divided into five core domains: pain, control and powerlessness, emotional well-being, social support, and self-image. Additionally, optional modular sections address areas like work, sexual relationships, and treatment concerns, providing a comprehensive understanding of how endometriosis affects daily life. Each domain is scored on a scale from 0 to 100, with 0 representing the best possible HRQoL (no impact of endometriosis) and 100 indicating the worst HRQoL (severe impact). Higher scores reflect greater impairment or distress caused by endometriosis in specific areas of life.
Time frame: At the beginning, at 3 and at 6 months.
Changes on quality of life assessed through the EuroQol5D (EQ-5D) questionnaire
The EQ-5D questionnaire is a standardized instrument developed to measure health-related quality of life (HRQoL). It is widely used in clinical settings, research, and health economic evaluations to assess the impact of diseases and treatments on an individual's overall health. The EQ-5D consists of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has levels of severity, typically ranging from no problems to extreme problems. The responses are combined into a single health state that can be converted into a utility score using a scoring algorithm. Utility scores range from -0.59 to 1, where 1 indicates perfect health and 0 represents a state equivalent to death.
Time frame: At the beginning, at 3 and at 6 months.
Number of reconsultations to the healtcare system assessed through medical assistance electronic records
Reconsultations in the healthcare system assessed through the medical assistance electronic records of the Catalan Healthcare system
Time frame: at 90 and 180 days:
Satisfaction with mobile health platform
Degree of satisfaction and usability with the mobile health platform. It will be measured through an online survey designed for the different ongoing studies that are using the MyPlan platform.
Time frame: At study completion (6 months).
Changes on Dysmenorrhoea pain scores assessed through a numerical rating scale (NRS)
Level of intensity of Dysmenorrhoea (NRS 0-10), with 0 representing no pain and 10 representing the worst imaginable pain
Time frame: At the beginning, at 3 and at 6 months.
Changes on Dyspareunia pain score assessed through a numerical rating scale (NRS)
Level of intensity of Dyspareunia (NRS 0-10), with 0 representing no pain and 10 representing the worst imaginable pain
Time frame: At the beginning, at 3 and at 6 months.
Changes on Dyschezia pain score assessed through a numerical rating scale (NRS)
Level of intensity of Dyschezia (NRS 0-10), with 0 representing no pain and 10 representing the worst imaginable pain
Time frame: At the beginning, at 3 and at 6 months.
Changes on Dysuria pain score assessed through a numerical rating scale (NRS)
Level of intensity of Dysuria (NRS 0-10), with 0 representing no pain and 10 representing the worst imaginable pain
Time frame: At the beginning, at 3 and at 6 months.
Changes on Omalgia pain score assessed through a numerical rating scale (NRS)
Level of intensity of Omalgia (NRS 0-10), with 0 representing no pain and 10 representing the worst imaginable pain
Time frame: At the beginning, at 3 and at 6 months.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau